Developing novel, well tolerated, treatments of cancer and inflammatory lung diseases

Developing novel, well tolerated, treatments of cancer and inflammatory lung diseases

Cantex has obtained exclusive worldwide rights from vTv Therapeutics to develop and commercialize azeliragon, a novel antagonist of RAGE (the receptor for advanced glycation endproducts)

company featured image
  • Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel, well tolerated, treatments of cancer and inflammatory lung diseases
  • Cantex is led by Stephen Marcus, M.D., and Neil Flanzraich, seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience

 

READ MORE

pipeline featured image
  • Azeliragon targets cancer and its complications as well as inflammatory lung diseases
  • Dicopp®, targets pediatric sarcoma
  • DSTAT for traumatic injury and hemorrhagic shock

 

READ MORE

doctor viewing vaccine

February 24, 2022 – Cantex Pharmaceuticals, Inc. announced that it has secured a global license from Harvard University’s Office of Technology Development (OTD) to further develop Cantex’s drug azeliragon into a treatment for inflammatory lung diseases including COVID-19.
READ MORE

 

September 14, 2021 – Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that it has sold 6.5 million shares of Chimerix, Inc. in brokerage transactions at a price of $5.75 per share, less brokerage commissions and fees.
READ MORE

DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML)